ArticleWorld journal of urology2025
Symptomatic presentation of renal cell carcinoma.
Article in World journal of urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Clear cell renal cell carcinoma presenting as isolated symptomatic lumbar vertebral metastasis: a case report.Frontiers in oncology · 2026Article
- Plasma exosomal lncRNA SLC16A1-AS1 as an early diagnostic biomarker for renal cell carcinoma.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposePrevalence of the classic triad of hematuria, flank pain and abdominal mass among renal cell carcinoma (RCC) patients appears to be declining, while incidence of RCC has increased. In addition, the relationship between symptomatic presentations and patient outcomes remains unclear. A contemporary analysis could provide insights into the stage-specific epidemiology of RCC symptoms and clarify impact on survival.
methodsRCC patients diagnosed between 2004 and 2017 were identified using SEER-Medicare data. Claims-based presentation of hematuria, abdominal pain, or abdominal mass within the preceding 12 months prior to diagnosis was captured. Multivariable logistic regression models were utilized to examine the relationship between patient characteristics and symptomatology. Survival outcomes were assessed using multivariable proportional hazards regression.
resultsAmong 47,369 RCC patients, 68.6% exhibited at least one symptom. Symptomatic patients decreased over time (p < 0.001). The classic triad of symptoms was observed in only 2.9% of patients and slightly more prevalent in later stage disease. Only those with the triad and abdominal mass specifically had increased risk of death [aHR 1.14 (95% CI 1.07–1.21) and aHR 1.05 (95% CI 1.01–1.08), respectively]. Five-year survival rates for patients with and without the symptom triad were 53.78% and 44.61% respectively.
conclusionAlthough a significant proportion of RCC patients may present with symptoms, the classic triad is rare. Presence of abdominal pain and hematuria symptoms alone did not demonstrate effect on survival rates. Decrease in symptomology and increase in the proportion of AJCC Stage 1 disease over time may be attributed to incidental detection.
Indexed as
Identifiers
41186677What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.